Evidence Review of Zepatier vs. Harvoni and Sovaldi for Hepatitis C

Evidence Review of Zepatier vs. Harvoni and Sovaldi for Hepatitis C

Summary:
Comparing 3 Direct-Acting Antiviral Agents for HCV: A Review of the Evidence

Jackie Syrop
Published Online: February 21, 2016

According to Advera’s report, as a standalone therapy Harvoni appears more effective in treatment-naïve patients, while Zepatier and Harvoni seem to have similar efficacy in treatment-experienced patients. Zepatier, Harvoni, and Sovaldi are direct-acting antiviral (DAA) agents that treat HCV.  

The analysis noted that Harvoni and Sovaldi are associated with AEs such as cardiac arrest, suicidal ideation, and suicide, while Zepatier’s label does not include these AEs. Initial analysis of Zepatier’s label showed comparatively fewer AEs (29 vs 41 for Sovaldi). Liver cirrhosis, the only Important Medical Event (IME) listed on the label, is largely associated with HCV and not with the drug.

Continue reading... 

Special Report Download
Evidence Review of Zepatier vs. Harvoni and Sovaldi for Hepatitis C

By Downloading this report you will:
Receive an in-depth review of the clinical safety and efficacy evidence for Zepatier (elbasvir, grazoprevir)

Understand how that evidence compares to Harvoni's (sofosbuvir, ledipasvir) and Sovaldi's (sofosbuvir) clinical evidence, including monograph ready tables

Gain access to the latest real world safety evidence on Harvoni and Sovaldi, including new safety signals and updated cost of side effect analysis

Drugs Included in this Report:
Zepatier (elbasvir, grazoprevir), Merck
Sovaldi (sofosbuvir), Gilead
Harvoni (ledipasvir and sofosbuvir), Gilead

For full access to this free report, please complete the form on this page.

Please note: This is an independent analysis conducted by Advera Health, based upon data and insight generated by the analytical tools of Adverse Events Explorer and other pertinent information gathered at the time of publication. This analysis is not sponsored or influenced by any third party. The inclusion of a particular company, drug, adverse event, class or indication in this report is determined wholly by our quantitative signaling and analytic systems along with our qualitative analysis work.

Begin here....